Literature DB >> 33064636

Is There a Role for Bismuth in Diarrhea Management?

Helen Senderovich1,2, Megan Vierhout1,3.   

Abstract

Diarrhea, an illness of both the developed and developing world, involves the burdensome characteristics of frequent bowel movements, loose stools, and abdominal discomfort. Diarrhea is a long-standing challenge in palliative care and can have a myriad of causes, making symptomatic treatment pertinent when illness evaluation is ongoing, when there is no definitive treatment approach, or when effective treatment cannot be attained. Symptomatic therapy is a common approach in palliative care settings. Bismuth is a suitable agent for symptomatic therapy and can be effectively employed for management of chronic diarrhea. The objective of this narrative review is to examine the role of bismuth in management of diarrheal symptoms. To explore this, PubMed (including Medline) and Embase were used to search the existing literature on bismuth and diarrhea published from 1980 to 2019. It was found that bismuth has potential utility for diarrheal relief in multiple settings, including microscopic colitis, traveler's diarrhea, gastrointestinal infection, cancer, and chemotherapy. It also has great potential for use in palliative care patients, due to its minimal side effects. Overall, the antisecretory, anti-inflammatory, and antibacterial properties of bismuth make it a suitable therapy for symptomatic treatment of diarrhea. The limited range of adverse side effects makes it an appealing option for patients with numerous comorbidities. Healthcare providers can explore bismuth as an adjunct therapy for diarrhea management in an array of conditions, especially in the palliative care setting.

Entities:  

Year:  2021        PMID: 33064636      PMCID: PMC7835118          DOI: 10.5041/RMMJ.10422

Source DB:  PubMed          Journal:  Rambam Maimonides Med J        ISSN: 2076-9172


  45 in total

Review 1.  Contemporary methods for the diagnosis and treatment of microscopic colitis.

Authors:  Aranzazu Jauregui-Amezaga; Séverine Vermeire; Karel Geboes
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-10-15       Impact factor: 3.869

2.  A new set of quality indicators for palliative care: process and results of the development trajectory.

Authors:  Susanne J J Claessen; Anneke L Francke; Hella E Belarbi; H Roeline W Pasman; Marianne J A van der Putten; Luc Deliens
Journal:  J Pain Symptom Manage       Date:  2011-03-23       Impact factor: 3.612

Review 3.  Current Approach to the Evaluation and Management of Microscopic Colitis.

Authors:  Thomas G Cotter; Darrell S Pardi
Journal:  Curr Gastroenterol Rep       Date:  2017-02

4.  Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea.

Authors:  H L DuPont; J Flores Sanchez; C D Ericsson; J Mendiola Gomez; M W DuPont; A Cruz Luna; J J Mathewson
Journal:  Am J Med       Date:  1990-06-20       Impact factor: 4.965

5.  Travellers' diarrhoea: causes, prevention and treatment.

Authors:  Rhoswen Lloyd; Clare Bennett
Journal:  Nurs Stand       Date:  2012 Jun 6-12

6.  Lymphocytic colitis: clinical features, treatment, and outcomes.

Authors:  Darrell S Pardi; Venktesh R Ramnath; Edward V Loftus; William J Tremaine; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2002-11       Impact factor: 10.864

7.  Prevention of traveler's diarrhea (emporiatric enteritis). Prophylactic administration of subsalicylate bismuth).

Authors:  H L DuPont; P Sullivan; D G Evans; L K Pickering; D J Evans; J J Vollet; C D Ericsson; P B Ackerman; W S Tjoa
Journal:  JAMA       Date:  1980-01-18       Impact factor: 56.272

8.  Prevention of traveler's diarrhea by the tablet form of bismuth subsalicylate.

Authors:  R Steffen; H L DuPont; R Heusser; A Helminger; F Witassek; M D Manhart; M Schär
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

Review 9.  Palliative Care in Older Patients With Cancer.

Authors:  Lodovico Balducci; Dawn Dolan; Sarah A Hoffe
Journal:  Cancer Control       Date:  2015-10       Impact factor: 3.302

10.  Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers.

Authors:  D Y Graham; M K Estes; L O Gentry
Journal:  Gastroenterology       Date:  1983-11       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.